相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Selumetinib in Children with Inoperable Plexiform Neurofibromas
Andrea M. Gross et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1
Amy E. Armstrong et al.
PEDIATRIC BLOOD & CANCER (2020)
Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation
Steven D. Rhodes et al.
HUMAN MOLECULAR GENETICS (2019)
Neurofibromatosis Clinical Trial Consortium
Roger J. Packer et al.
JOURNAL OF CHILD NEUROLOGY (2018)
PedsQL Neurofibromatosis Type 1 Module for children, adolescents and young adults: feasibility, reliability, and validity
Kavitha Nutakki et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1
Andrea M. Gross et al.
NEURO-ONCOLOGY (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients
Sara M. Tolaney et al.
ONCOLOGIST (2017)
Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial
Maria E. Cabanillas et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies
Marie Schoumacher et al.
CURRENT ONCOLOGY REPORTS (2017)
A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies
Ophelia Maertens et al.
CANCER RESEARCH (2017)
Giving AXL the axe: targeting AXL in human malignancy
Carl M. Gay et al.
BRITISH JOURNAL OF CANCER (2017)
Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas
Michael J. Ferguson et al.
PEDIATRIC BLOOD & CANCER (2016)
Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults
Linh Nguyen et al.
ANTI-CANCER DRUGS (2016)
Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers
Rebecca Lock et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial
Raya Leibowitz-Amit et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Eva Dombi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1
Edwin Jousma et al.
PEDIATRIC BLOOD & CANCER (2015)
Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study
Brian Weiss et al.
NEURO-ONCOLOGY (2015)
A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor
Nancy Ratner et al.
NATURE REVIEWS CANCER (2015)
Cabozantinib-Induced Thyroid Dysfunction: A Review of Two Ongoing Trials for Metastatic Bladder Cancer and Sarcoma
Sahzene Yavuz et al.
THYROID (2014)
Optimizing biologically targeted clinical trials for neurofibromatosis
David H. Gutmann et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer
David Viola et al.
FUTURE ONCOLOGY (2013)
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors
Walter J. Jessen et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Achieving consensus for clinical trials The REiNS International Collaboration
Scott R. Plotkin et al.
NEUROLOGY (2013)
Recommendations for imaging tumor response in neurofibromatosis clinical trials
Eva Dombi et al.
NEUROLOGY (2013)
Pathogenesis of Plexiform Neurofibroma: Tumor-Stromal/Hematopoietic Interactions in Tumor Progression
Karl Staser et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 7 (2012)
Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
James S. Duncan et al.
CELL (2012)
Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial
Kent A. Robertson et al.
LANCET ONCOLOGY (2012)
Preclincial testing of Sorafenib and RAD001 in the Nfflox/flox;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging
Jianqiang Wu et al.
PEDIATRIC BLOOD & CANCER (2012)
Polychromatic Flow Cytometry Identifies Novel Subsets of Circulating Cells with Angiogenic Potential in Pediatric Solid Tumors
Kamnesh R. Pradhan et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2011)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
CLINICAL EXPERIENCE WITH RADIATION THERAPY IN THE MANAGEMENT OF NEUROFIBROMATOSIS-ASSOCIATED CENTRAL NERVOUS SYSTEM TUMORS
Stacy Wentworth et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
Nf1-Dependent Tumors Require a Microenvironment Containing Nf1+/- and c-kit-Dependent Bone Marrow
Feng-Chun Yang et al.
CELL (2008)
Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1
Victor-F. Mautner et al.
NEURO-ONCOLOGY (2008)
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Marcus Bantscheff et al.
NATURE BIOTECHNOLOGY (2007)
NF1 plexiform neurofibroma growth rate by volumetric MRI - Relationship to age and body weight
E. Dombi et al.
NEUROLOGY (2007)
Neurofibroma-associated growth factors activate a distinct signaling network to alter the function of neurofibromin-deficient endothelial cells
Amy M. Munchhof et al.
HUMAN MOLECULAR GENETICS (2006)
Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging
J Solomon et al.
COMPUTERIZED MEDICAL IMAGING AND GRAPHICS (2004)
Malignant peripheral nerve sheath tumours in neurofibromatosis 1
DGR Evans et al.
JOURNAL OF MEDICAL GENETICS (2002)
Defining the clinically important difference in pain outcome measures
JT Farrar et al.
PAIN (2000)
分享论文
